The IgA Nephropathy (IgAN) market is being propelled by several key factors. A major driver is the rising prevalence of the disease and improvements in diagnostic capabilities, as increased awareness among healthcare professionals and advanced diagnostic tools enable earlier and more precise detection. The substantial unmet medical need also fuels market growth, as existing treatment options are limited and many patients progress to end-stage renal disease (ESRD), creating demand for more effective and targeted therapies. According to DelveInsight, the IgA Nephropathy pipeline includes 30+ pharmaceutical and biotech companies developing over 25 therapeutic candidates targeting IgAN. These therapies span multiple stages of clinical and preclinical development, highlighting the sector’s strong innovation and commitment to addressing a significant public health challenge.
DelveInsight’s “IgA Nephropathy Pipeline Insight 2025” report offers a comprehensive and strategic analysis of the current R&D landscape. It details clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report is an essential resource for stakeholders—including researchers, healthcare investors, and decision-makers—seeking insights into the evolving IgA Nephropathy therapeutics market and the innovations shaping its future.
Explore the Cutting-Edge Landscape of IgA Nephropathy Drug Development @ https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Key Takeaways from the IgA Nephropathy Pipeline Report
-
DelveInsight’s IgA Nephropathy pipeline report highlights a dynamic landscape with 25+ active companies developing over 30 therapeutic candidates for the treatment of IgAN.
-
In April 2025, the FDA approved Vanrafia® (atrasentan), an endothelin A receptor antagonist developed by Novartis, representing a major advancement in IgAN therapy. This approval was supported by clinical evidence showing its effectiveness in reducing proteinuria, a critical marker of kidney function decline in IgAN patients.
-
In August 2024, Novartis also received accelerated FDA approval for Fabhalta® (iptacopan), a first-in-class complement inhibitor targeting the alternative complement pathway. This therapy has demonstrated potential in lowering proteinuria in adults with primary IgAN at high risk of rapid disease progression.
-
Key players in the IgA Nephropathy market—such as Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Selecta Biosciences, Shanghai Alebund Pharmaceuticals, and others—are actively developing new therapies to enhance treatment options.
-
Promising pipeline candidates include Atrasentan, SHR-2010, TAK-079, among others.
IgA Nephropathy Overview:
IgA nephropathy (IgAN), also referred to as Berger’s disease, is the most common primary glomerular disorder and can potentially progress to end-stage renal disease (ESRD). It is classified as an autoimmune condition, arising from interactions between galactose-deficient IgA1 (an intrinsic antigen) and circulating anti-glycan antibodies. IgA is an antibody produced by the immune system to help defend against infections caused by bacteria and viruses.
IgAN is most frequently observed in Caucasian and Asian males, typically appearing between adolescence and the late 30s, though it can develop at any age. While many patients experience stable disease or spontaneous improvement, some may progress to ESRD over 20–25 years. In rare cases, untreated individuals can experience rapid kidney failure within a few years.
Symptoms vary widely, ranging from blood or protein in the urine to severe hypertension resulting from kidney damage. The degree of tubulointerstitial injury is closely associated with the rate of kidney function decline and long-term renal prognosis. Due to persistent underlying immune dysfunction, IgAN may recur even after kidney transplantation.
Download the IgA Nephropathy sample report to know in detail about the IgA Nephropathy treatment market @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
IgA Nephropathy Pipeline Analysis
The IgA Nephropathy pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the IgA Nephropathy Market.
-
Categorizes IgA Nephropathy therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging IgA Nephropathy drugs under development based on:
-
Stage of development
-
IgA Nephropathy Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
IgA Nephropathy Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
IgA Nephropathy Licensing agreements
-
Funding and investment activities supporting future IgA Nephropathy market advancement.
-
Unlock key insights into emerging IgA Nephropathy therapies and market strategies here: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
IgA Nephropathy Emerging Drugs
-
Atrasentan: Chinook Therapeutics
Atrasentan is a potent and highly selective endothelin A receptor (ETA) antagonist that has shown potential in managing various chronic kidney diseases by reducing proteinuria and providing anti-inflammatory and anti-fibrotic benefits to help maintain kidney function. Chinook selected IgA nephropathy (IgAN) as the main focus for atrasentan development because ETA activation contributes significantly to proteinuria, mesangial cell activation, kidney inflammation, and fibrosis—key factors driving IgAN progression. The drug is currently undergoing Phase III clinical trials for IgAN treatment.
-
SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.
SHR-2010 is an experimental therapy being developed for the treatment of Primary IgA Nephropathy by Guangdong Hengrui Pharmaceutical Co., Ltd. Administered through injection, the drug is currently in Phase II clinical trials. It targets the MASP-2 protein, with ongoing studies evaluating its efficacy, safety, and pharmacokinetic profile in patients with Primary IgA Nephropathy.
-
TAK-079: Takeda
TAK-079, also called mezagitamab, is designed to target and eliminate CD38-expressing cells, including plasmablasts, plasma cells, and natural killer cells. In IgA nephropathy, its therapeutic rationale is to reduce the population of plasma cells producing abnormal IgA1, thereby preventing the formation of pathogenic immune complexes and subsequent kidney damage. The drug is currently being evaluated in a Phase 1b clinical trial to assess its safety, tolerability, pharmacokinetics, and efficacy in patients with primary IgA nephropathy who are receiving stable background therapy.
IgA Nephropathy Pipeline Therapeutic Assessment
IgA Nephropathy Assessment by Product Type
• Mono
• Combination
• Mono/Combination
IgA Nephropathy By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
IgA Nephropathy Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
IgA Nephropathy Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging IgA Nephropathy therapies and key IgA Nephropathy companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. IgA Nephropathy Current Treatment Patterns
4. IgA Nephropathy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. IgA Nephropathy Late-Stage Products (Phase-III)
7. IgA Nephropathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. IgA Nephropathy Discontinued Products
13. IgA Nephropathy Product Profiles
14. IgA Nephropathy Key Companies
15. IgA Nephropathy Key Products
16. Dormant and Discontinued Products
17. IgA Nephropathy Unmet Needs
18. IgA Nephropathy Future Perspectives
19. IgA Nephropathy Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the IgA Nephropathy pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/